Solace Therapeutics, Inc. Release: Six-Month Data From The SOLECT Trial Awarded One Of The “Best” Poster Presentations At The Upcoming 31st European Association Of Urology (EAU) Congress In Munich, Germany

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Solace Therapeutics, Inc., announced today that Stefan De Wachter, MD, PhD, will be presenting six-month data from the SOLECT Trial during the 31^st Annual EAU Congress in Munich, Germany on Saturday, March 12. The poster has been awarded “best” poster within the category of “Slings and Things in Female Incontinence.”

The poster presentation includes six-month data which had been collected from on-going follow-up of patients enrolled in the Company’s second Randomized Controlled Trial of the Vesair^® Bladder Control System. The results demonstrate that patients continue to experience clinically relevant efficacy in the reduction of urine leakage, episode frequency, and improved Quality of Life six months after receiving the balloon. “I was pleased to see patients experiencing such good results. The Vesair Bladder Control Balloon procedure is a great alternative for those women with stress urinary incontinence who don’t want to perform or who do not benefit from Kegel exercises as well as for those women who don’t see surgery as a viable alternative.” said Stefan De Wachter, MD, PhD, one of several investigators for the SOLECT Trial, at Universitair Ziekenhuis Antwerpen, Edegem, Belgium.

Three-month study results from the trial were published online in The Journal of Neurourology and Urodynamics in 2015. This study is the second peer-reviewed publication to publish study results on the safety and effectiveness of intravesical pressure attenuation. To review the published study, go to: http://onlinelibrary.wiley.com/doi/10.1002/nau.22708/abstract.

About Stress Urinary Incontinence and the Vesair Bladder Control System

Women with SUI typically experience transient increases in intravesical pressure during physical movement; for example, when coughing, laughing, sneezing, or during exercise. When this increased bladder pressure exceeds the ability of the urethral sphincter to withstand it, leakage occurs. Unlike currently available SUI treatments that focus on improving the urethral closure forces, the Vesair Bladder Control Balloon is designed to reduce rapid increases in bladder pressure through the placement of a compressible air-filled balloon in the bladder. The balloon acts like a “shock absorber” to slow rapid changes in pressure and reduce leakage. The uninflated balloon is placed into the bladder through the urethra and subsequently inflated. Balloon placement is performed as an out-patient procedure that does not require anesthesia, and the balloon is intended to remain in the bladder for up to 12 months and replaced annually. The Vesair Bladder Control System is for investigation use only in the United States and has CE mark approval for distribution within the European Union (EU).

About Solace Therapeutics, Inc.

Solace Therapeutics is an emerging medical technology company primarily focused on a revolutionary non-surgical office-based treatment for symptoms of SUI. SUI affects nearly 30 million women globally and can occur in nearly 40% of all men who have prostate surgery. The cost of caring for patients with incontinence is a significant economic burden on the healthcare delivery system if left untreated. Solace is dedicated to developing value-driven innovations that can help healthcare providers improve patient outcomes, reduce procedure costs, and enhance the quality of life for people whose daily activities are disrupted by their incontinence. The Company has completed enrollment into their third randomized controlled trial, the SUCCESS clinical trial. Data from these trials will support the application for FDA clearance, third-party reimbursement and patient adoption. Please visit www.solacetx.com to learn more about the Company.